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PATHOLOGIC CONFIRMATION OF RETINAL
GANGLION CELL LOSS IN MULTIPLE SYSTEM
ATROPHY
Multiple system atrophy (MSA) is a rare adult-onset
rapidly progressive fatal neurodegenerative disorder
characterized by the abnormal aggregation of mis-
folded a-synuclein primarily in oligodendrocytes.1
In vivo studies of retinal structure using optical
coherence tomography (OCT) have shown a remark-
able reduction in the thickness of the retinal ganglion
cell layer (GCL) and their axons in the retinal nerve
fiber layer (RNFL) in patients with MSA.2 These
retinal abnormalities worsen over time and are asso-
ciated with motor and overall clinical worsening.2
Here we report a detailed neuropathologic assess-
ment of the retina in 3 patients (6 eyes) with
autopsy-proven MSA, well-characterized clinically
while alive. All 3 patients were women with the cere-
bellar predominant phenotype. Patient 1 died at age
69; she had been bedridden for 15 months and died
during her sleep 10 years after disease onset. Patient 2
died at age 59; she had been bedridden for 4 months
and died of pulmonary embolism and respiratory fail-
ure 7 years after disease onset. Patient 3 was a 61-year-
old woman who became bedridden 7 months prior to
death and died during sleep 8 years after disease onset.
In patients 1 and 2, comprehensive neuro-
ophthalmologic evaluations including OCT (e-Methods
at Neurology.org) had been performed 18 and 5
months before death, respectively. Four eyes from
4 age-matched normal subjects with no ophthalmo-
logic or neurologic conditions were also studied
as controls. The reported cause of death in the 4
controls was cardiorespiratory arrest.
Eyes were fixed in neutral-buffered 10% formalin
and retinal whole mounts prepared. To increase anti-
body penetration, retinal whole mounts were cryo-
protected with 30% sucrose in 0.1 M phosphate
buffer and subjected to a freeze–thaw cycle. Wedge-
shaped pieces of retina were immunohistochemically
stained as free-floating preparations with blue fluores-
cent Hoechst 33258 pentahydrate (bisbenzimide)
(Molecular Probes, Eugene, OR). Analogous samples
were stained using a mouse monoclonal antibody
against a-synuclein phosphorylated at serine 129
(1:1,000; Wako Chemicals, Richmond, VA; clone
no. pSyn#64). Retinal whole mounts were mounted
in Citifluor (Citifluor Ltd., London, UK) and
observed in a TCS SP2 confocal laser scanning micro-
scope or in a Leica DMR microscope (Leica Micro-
systems, Wetzlar, Germany). Cells in the GCL were
manually counted in 7 1-mm concentrically defined
annular areas centered in the fovea, using a previously
reported method.3 A total of 7 retinal whole mounts
for blue fluorescent Hoechst (3 MSA and 4 control)
and 5 whole mounts for anti-a-synuclein phosphor-
ylated staining (3 MSA and 2 control) were prepared.
Clinical neuro-ophthalmologic examination,
visual acuity, color discrimination, and funduscopy
were normal in patient 1 (69-year-old woman),
patient 2 (59-year-old woman), and patient 3 (61-
year-old woman). OCT in patients 1 and 2 showed
generalized thinning of the RNFL, more evident in
the inferior quadrant of the RNFL, where the axons
of the peripheral ganglion cells are located. The thick-
ness of the ganglion cell complex at the macular area
was also reduced (figure).
Histopathologic analysis of the Hoechst-stained ret-
inae showed diffuse retinal ganglion cell loss in the eyes
of patients with MSA compared to controls (figure).
This difference was more pronounced in the peripheral
retina rather than in the central retina. In patients with
MSA, reduced density of ganglion cells was associated
with longer distances from the central retina (figure).
a-Synuclein staining failed to show aggregates of phos-
phorylated a-synuclein in the GCL of any of the 3
patients with MSA or the control retinae.
These histopathology findings in the retinae of pa-
tients with MSA confirm our previous in vivo observa-
tions using OCT indicating that the retinal ganglion
cells and their axons in the RNFL were reduced in
these patients.2 A more severe retinal ganglion cell loss
in the peripheral retina, rather than in the macular
area (central retina), had also been observed with
OCT. The partial sparing of the central retinal gan-
glion cells with the brunt of the loss in the peripheral
retina may explain why patients with MSA are visually
asymptomatic and do not exhibit significant loss of
visual acuity or color discrimination, as both are func-
tions of the central macular ganglion cells.
Abnormal a-synuclein aggregates have been re-
ported in the retinal ganglion cells of patients with
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Parkinson disease4,5 but we did not find similar ag-
gregates in patients with MSA. In the brain of pa-
tients with Parkinson disease, accumulation of
a-synuclein occurs in neurons,6 whereas in MSA
brains, pathologic a-synuclein aggregates occur
mostly in oligodendroglial cells.1 Because there are
no oligodendroglial cells in the retina, it is conceivable
that the abnormal a-synuclein deposits in patients
with MSA occur in oligodendroglial cells in the optic
nerve. Optic nerve oligodendroglial cells myelinate
the axons of magnocellular ganglion cells, which are
located in the retinal areas most affected in patients
with MSA. Our small sample size precluded statistical
correlations between OCT findings and ganglion cell
density, which should be addressed in future studies.
We report neuropathologic evidence that retinal
ganglion cells are reduced in patients with MSA, an
abnormality that had previously been reported
in vivo using OCT. These findings provide further
support for the use of retinal thickness as measured
by OCT as a potential biomarker of efficacy of
disease-modifying agents in patients with MSA.
*These authors contributed equally to this work.
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Figure Immunohistochemical analysis of retinal ganglion cells in multiple system atrophy (MSA) and its in vivo
correlation with optical coherence tomography (OCT)
Confocal images of representative areas of whole-mounted retinae (superior–temporal area) labeled with the blue fluo-
rescent Hoechst marker of a patient with MSA (A, C, E) and a normal control (B, D, F). Distance from the peripheral retina (ora
serrata): center: 11–13 mm; middle: 5–9 mm; periphery: 1–3 mm. Scale bar is 100 mm. The number of ganglion cells is
markedly reduced in MSA compared to controls. These pathologic findings are similar to those found with in vivo OCT. (G, H)
OCT macular sections where the different layers of the retina can be appreciated. The ganglion cell layer (GCL) complex
(delimited with a dashed red line) is thinner in a patient with MSA (H) compared to an age-matched normal control (G). In the
same patient with MSA, the thickness of the inferior quadrant of the retinal nerve fiber layer (I) and the macular ganglion cell
complex layer (J), measured by OCT, are substantially reduced (reduced thickness identified in yellow and red). These
findings were confirmed with ganglion cell quantification, where retinal ganglion cell loss was consistent in the entire retina,
particularly in the far peripheral areas (K). Briefly, images of the whole retinal sample (with the focus on the GCL) were taken
and sampling regions of 1 mm2 were established every 2 mm from the ora serrata to the central retina. Cells in the GCL
stained with Hoechst were manually counted and the mean density of cells in each quadrant (number of cells per mm2) was
calculated for MSA and controls. The percentage of ganglion cell loss at each sampling region in patients with MSA (with the
ganglion cell count of controls as reference) is shown (K).
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